SynthesisSeminars in thrombosis and hemostasis2012
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).
Synthesis in Seminars in thrombosis and hemostasis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Efficacy of Poloxamer 188 in Experimental Myelosuppression Model Induced by Carboplatin in CBA Mice.International journal of molecular sciences · 2025Article
- Lipidization as a tool toward peptide therapeutics.Drug delivery · 2023Review
- Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review.Biomedicines · 2023Review
- Inflammation alters iron distribution in bone and spleen in mice.Metallomics : integrated biometal science · 2023Article
- Peptides GWN and GW protect kidney cells against Dasatinib induced mitochondrial injury in a SIRT1 dependent manner.Food chemistry. Molecular sciences · 2022Article
- The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.The oncologist · 2021Review
- Review
- Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma.Clinical epidemiology · 2018Article
- Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammation.Wiener medizinische Wochenschrift (1946) · 2016Review
- Pre-operative anaemia: prevalence, consequences and approaches to management.Blood transfusion = Trasfusione del sangue · 2015Review
- Regulatory and clinical considerations for biosimilar oncology drugs.The Lancet. Oncology · 2014Review
- Anaphylaxis and hypotension after administration of peginesatide.The New England journal of medicine · 2014Article
- The pathophysiology and pharmacology of hepcidin.Trends in pharmacological sciences · 2014Review
- Perioperative anemia management in colorectal cancer patients: a pragmatic approach.World journal of gastroenterology · 2014Review
- Manipulation of the hepcidin pathway for therapeutic purposes.Haematologica · 2013Review
- Article
- The Janus faces of ESAs: caveat Chimaera!International urology and nephrology · 2013Review
- Anaemia management and mortality risk in chronic kidney disease.Nature reviews. Nephrology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical trials, meta-analyses, and guidelines identify mortality, tumor progression, and venous thromboembolism (VTE) risks with ESA administration in this setting. Product labels advise against administering ESAs with potentially curative chemotherapy (United States) or to conduct risk-benefit assessments (Europe/Canada). Since 2007, fewer chemotherapy-associated anemia patients in the United States and Europe receive ESAs. ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. U.S. labels recommend administering ESAs or peginesatide at doses sufficient to prevent transfusions among dialysis CKD patients. For dialysis CKD patients, Canadian and European labels recommend targeting hemoglobin levels of 10 to 12 g/dL and 11 to 12 g/dL, respectively, with ESAs. ESA utilization for dialysis CKD patients has decreased in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.